Get the Stockscreener App
0.9342
2.56%
-0.0233
Ocugen Inc stock is traded at $0.9342, with a volume of 931.00K.
It is down -2.56% in the last 24 hours and down -7.62% over the past month.
Ocugen Inc company focused on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve health and offer hope for patients across the globe. The company's pipeline includes Modifier Gene Therapy Platform, Novel Biologic Therapy for Retinal Diseases, Regenerative Medicine Cell Therapy Platform. The company is developing a modifier gene therapy platform designed to fulfill unmet medical needs related to retinal diseases, including inherited retinal diseases ("IRDs"), such as RP, LCA, Stargardt disease, and multifactorial diseases such as dAMD and Geographic Atrophy ("GA").
See More
Previous Close:
$0.9575
Open:
$0.95
24h Volume:
931.00K
Relative Volume:
0.27
Market Cap:
$275.62M
Revenue:
-
Net Income/Loss:
$-63.08M
P/E Ratio:
-2.5249
EPS:
-0.37
Net Cash Flow:
$-72.53M
1W Performance:
-3.15%
1M Performance:
-7.62%
6M Performance:
-29.85%
1Y Performance:
+142.34%
1-Day Range:
$0.93
$0.96
1-Week Range:
$0.9032
$1.02
52-Week Range:
$0.351
$2.105
Ocugen Inc Stock (OCGN) Company Profile
Name
Ocugen Inc
Sector
Industry
Phone
484-328-4701
Address
11 GREAT VALLEY PARKWAY, MALVERN, PA
Ocugen Inc Stock (OCGN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-01-23 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Aug-23-22 | Initiated | Mizuho | Buy |
| Jun-15-22 | Resumed | ROTH Capital | Buy |
| Jun-02-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jul-26-21 | Initiated | Noble Capital Markets | Outperform |
| Jun-11-21 | Downgrade | ROTH Capital | Buy → Neutral |
| May-07-21 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Feb-09-21 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Feb-04-21 | Upgrade | H.C. Wainwright | Neutral → Buy |
View All
Ocugen Inc Stock (OCGN) Latest News
Vanguard Group Inc's Strategic Acquisition of Shares in Ocugen I - GuruFocus.com
Ocugen to Spotlight Gene Therapy Advances at Upcoming Clinical Showcase - MSN
Ocugen (OCGN) Set to Announce Earnings on Friday - MarketBeat
Those who invested in Ocugen (NASDAQ:OCGN) a year ago are up 163% - Yahoo Finance
Ocugen Inc. stock rises Wednesday, outperforms market - MarketWatch
Ocugen Inc. stock falls Tuesday, underperforms market - MarketWatch
Ocugen Inc. stock rises Monday, outperforms market - MarketWatch
Ocugen Clinical Showcase Highlighting Progress in Retinal Gene Therapy Clinical Trials in New York City on Tuesday, November 12, 2024 - Ocugen
Ocugen Clinical Showcase Highlighting Progress in Retinal - GlobeNewswire
Ocugen Inc. stock rises Friday, outperforms market - MarketWatch
Ocugen Inc. stock falls Thursday, underperforms market - MarketWatch
Ocugen Advances Stargardt Disease Trial with Promising Gene Therapy - MSN
Ocugen Inc. stock falls Wednesday, underperforms market - MarketWatch
HC Wainwright Reiterates Buy Rating for Ocugen (NASDAQ:OCGN) - MarketBeat
Data and Safety Monitoring Board Approves Initiation of Phase 2 of OCU410ST GARDian Clinical Trial for Stargardt Disease - Ocugen
Ocugen advances to phase 2 in Stargardt disease trial - Investing.com
Data and Safety Monitoring Board Approves Initiation of - GlobeNewswire
Ocugen to Host Conference Call on Friday, November 8 at - GlobeNewswire
Ocugen to Host Conference Call on Friday, November 8 at 8:30 A.M. ET to Discuss Business Updates and Third Quarter 2024 Financial Results - StockTitan
State Street Corp's Strategic Acquisition of Shares in Ocugen Inc - Yahoo Finance
Ocugen Inc. stock outperforms market despite losses on the day - MarketWatch
Maxim Group sees Ocugen shares as a buy, cites financial position - Investing.com
Ocugen (NASDAQ:OCGN) Receives New Coverage from Analysts at Maxim Group - MarketBeat
Ocugen Advances Promising Pipeline Amid Financial Restraints - Nasdaq
Ocugen’s CEO to Present at 2024 Maxim Healthcare Virtual Summit - MSN
Ocugen to Participate in 2024 Maxim Healthcare Virtual Summit - Ocugen
Ocugen says FDA has removed clinical hold on eye drug OCU200 - MSN
Ocugen Inc (OCGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - Yahoo Finance
Ocugen Inc (OCGN) Q2 2024 Earnings Call Highlights: Strategic Advances Amid Financial Challenges By GuruFocus - Investing.com Canada
Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for OCU200 Phase 1 Clinical Trial - Ocugen
FDA lifts hold on Ocugen's DME drug trial - Investing.com
Ocugen Says FDA Lifts Clinical Hold on Diabetic Macular Edema Drug - MarketWatch
Ocugen, Inc. Announces Removal of Clinical Hold on Investigational New Drug Application for - The Bakersfield Californian
Ocugen, Inc. Announces Removal of Clinical Hold on - GlobeNewswire
Ocugen, Inc. to Feature at Chardan’s Genetic Medicines Conference - MSN
WashU COVID-19 nasal vaccine technology licensed to Ocugen - WashU Medicine
OCGN INVESTOR ALERT: Bronstein, Gewirtz & Grossman LLC - GlobeNewswire
Cheese Block (BGU25) Quote - The Globe and Mail
Ocugen, Inc. Set to Present at 2024 Cell & Gene Meeting on the Mesa - MSN
Ocugen to Present at the 2024 Cell & Gene Meeting on the Mesa - Ocugen
Apple Inc (AAPL-Q) QuotePress Release - The Globe and Mail
Profund Advisors LLC Invests $227,000 in Ocugen, Inc. (NASDAQ:OCGN) - Defense World
Ocugen’s CSO to Highlight Gene Therapy Advances at Upcoming Conference - MSN
Long-Term Investors in Ocugen, Inc. (NASDAQ: OCGN) shares - openPR
Ocugen Inc Stock (OCGN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.75%
0.20%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):